11 Recruiting Thyroid Cancer Phase 2 Clinical Trials
Active phase 2 studies for thyroid cancer enrolling across the USA. Verify eligibility and contact site coordinators.
All Thyroid Cancer studiesPhase 2 Studies for Thyroid Cancer
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
📍 Stanford University — Palo Alto, California
View Study & Checklist ➔Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
📍 University of Chicago Comprehensive Cancer Center — Chicago, Illinois
View Study & Checklist ➔Vemurafenib Neoadjuvant Trial in Locally Advanced Thyroid Cancer
📍 University of Texas MD Anderson Cancer Center — Houston, Texas
View Study & Checklist ➔Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Thyroid Cancer
📍 Memorial Sloan Kettering Cancer Center — Basking Ridge, New Jersey
View Study & Checklist ➔177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
📍 University of California, San Francisco — San Francisco, California
View Study & Checklist ➔Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
📍 MedStar Washington Hospital Center — Washington D.C., District of Columbia
View Study & Checklist ➔The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
View Study & Checklist ➔A Study of Avutometinib and Defactinib in People With Thyroid Cancer
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
📍 Washington University School of Medicine — St Louis, Missouri
View Study & Checklist ➔